Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
1,479
Total Claims
$3.2M
Drug Cost
270
Beneficiaries
$12K
Cost/Patient
Risk Score Breakdown 11/100
Score components are additive. Read full methodology
Peer Comparison vs. 3,372 Medical Oncology providers
-11%
Opioid rate vs peers
5.2% vs 5.9% avg
-4%
Cost per patient vs peers
$12K vs $12K avg
+33%
Brand preference vs peers
17.9% vs 13.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
5.2%
Opioid Rate
77
Opioid Claims
$18K
Opioid Cost
15.6%
Long-Acting Rate
Brand vs Generic
Brand: 260 claims · $2.9M
Generic: 1,193 claims · $324K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Ivosidenib | 12 | $376K |
| Ruxolitinib Phosphate | 13 | $243K |
| Palbociclib | 13 | $217K |
| Osimertinib Mesylate | 12 | $189K |
| Abemaciclib | 11 | $184K |
| Enzalutamide | 12 | $182K |
| Ibrutinib | 14 | $166K |
| Abiraterone Acetate | 21 | $142K |
| Lenalidomide | 11 | $137K |
| Lipase/Protease/Amylase | 11 | $82K |
| Rivaroxaban | 27 | $35K |
| Apixaban | 34 | $31K |
| Imatinib Mesylate | 11 | $14K |
| Anastrozole | 133 | $3,317 |
| Letrozole | 116 | $3,187 |
Prescribing Profile
Patient Profile
73
Avg Age
70%
Female
2.02
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About